ASCP Corner: Are Nutritional Supplements Ready for Prime Time?
J Clin Psychiatry 2008;69(9):1497-1498
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Over the past 20 years, there has been a surge of clinical trials
examining the safety and efficacy of natural compounds for
psychiatric indications. These studies have produced encouraging
evidence for several putative antidepressants such as
S-adenosyl-L-methionine (SAMe), St. John’s wort (SJW), the
omega-3 fatty acids, and folic acid.
There are about 45 published randomized controlled trials
(RCTs) of SAMe monotherapy against placebo or tricyclic antidepressants